Jan 31, 2019
Believe Limited and The Foundation for Art & Healing Survey Results Underscore the Importance of Connection and Community in Managing a Chronic Rare Disease
Dec 17, 2018
Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B
Oct 05, 2018
Global Hemophilia Market and Competitive Landscape 2014-2018 & 2023
Oct 02, 2018
Octapharma USA Sponsors The Female Factor Women's Retreat in Monterey
Sep 12, 2018
Octapharma USA Partners with GutMonkey To Provide Hemophilia Patients Life-Changing Adventure Experience
Jul 26, 2018
Hemophilia Federation of America seeks archival records to recognize 25 years serving the bleeding disorders community
Jul 09, 2018
BioMarin Partners with Believe Limited for 'Breaking Through!' Musical Theater Intensive
May 31, 2018
IDELVION® Newly Approved 3500 IU Vial to Provide Convenience to Patients Using Larger Volumes
May 23, 2018
FDA Accepts Supplemental Biologics License Application (BLA) and Grants Priority Review for Prophylactic and Pediatric Use for Bio Products Laboratory's Coagadex® (Coagulation Factor X, Human) for Treatment of Hereditary Factor X Deficiency
May 21, 2018
Head-to-head pharmacokinetic study demonstrated greater factor IX activity with Rebinyn® versus rFIXFc in people with hemophilia B
May 21, 2018
Sobi Emphasises Commitment to Haemophilia Community at WFH 2018 World Congress
Apr 16, 2018
GC Pharma Marks 'World Haemophilia Day'
Apr 16, 2018
World Hemophilia Day 2018: Sharing Knowledge Makes Us Stronger
Apr 11, 2018
Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada
Mar 29, 2018
CVS Health Announces $260,000 in New Support for Bleeding Disorder Programs
Feb 28, 2018
Sobi Launches Enhanced Corporate Sustainability Initiative
Feb 15, 2018
Oxford BioMedica Announces Collaboration and Licence Agreement with Bioverativ in the Field of Haemophilia Gene Therapy
Feb 12, 2018
Research Study Results Presented at EAHAD 2018
Feb 08, 2018
Novo Nordisk Launches Rebinyn® in the United States for People with Hemophilia B
Feb 07, 2018
The Republic of Ireland Switches all People With Haemophilia A & B Treated With Replacement Clotting Factors to Sobi's(TM) Extended Half-life Therapies